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The cellular pathway of autophagy has emerged from the periph-
ery of biomedicine into the spotlight. Literally meaning ‘self-
eating’, our understanding of autophagy has evolved with a
history in the scientiﬁc literature similar to what previously
occurred with the study of apoptosis – ﬁrst described as a mor-
phologic curiosity, it is now clear that autophagy, like apoptosis,
is a tightly regulated pathway that maintains cellular homeosta-
sis, with important disease implications relevant to cancer,
inﬂammation and immunity, genetic diseases, and ﬁbrosis,
among others. Also like apoptosis, a cascade of speciﬁc effector
proteins has been uncovered that link autophagic pathways to
changes in cell structure and function. Collectively known as
‘‘ATG’’ proteins (with 30 identiﬁed to date), these autophagic
mediators integrate a number of convergent signals to either
accelerate intracellular recycling and cell survival, or sometimes
provoke cell death [1,2]. Strictly, there are three types of autoph-
agy: macroautophagy, microautophagy, and chaperone-mediated
autophagy [3,4], but macroautophagy is the focus of most human
disease studies, where its primary role is to degrade intracellular
organelles and protein aggregates that are too large to be broken
down by the proteasome. Morphologically, autophagy is com-
prised of series of well-deﬁned steps: formation of a double-
membrane around an organelle to generate an autophagosome,
followed by its fusion with a lysosome to form an autolysome,
and then degradation of the contents by lysosomal enzymes.
While the breadth of autophagy’s roles is still not fully appre-
ciated, its most cogent evolutionary function is to preserve cellu-
lar energy homeostasis. There is a basal level of autophagy in
normal cells that provides a quality control mechanism to clear
damaged organelles or protein aggregates. However, autophagy
is induced in the midst of inadequate nutrient supply or stress.
Thus, starvation is the classic trigger that initiates autophagy to
provide fuel through consumption of intracellular substrates. In
this context, the interest in autophagy in studies of liver was
greatly accelerated by a seminal study by Mark Czaja and col-
leagues in 2009 [5], who demonstrated that hepatocytes con-
sume intracellular lipid when they are starved. This advance
has led to a broader focus on how autophagy regulates cellularJournal of Hepatology 20
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to disease, or might be exploited to establish new treatments.
The most immediate liver disease-relevance of autophagy is in
alpha1-antitrypsin disease, where increased autophagic ﬂux
occurs in cells that have accumulated the mutant protein, and
where inhibition of autophagy greatly delays alpha1-antitrypsin
degradation [6]. Based on this ﬁnding, David Perlmutter and col-
leagues demonstrated that carbamazepine, an anti-convulsant
CNS drug known to promote autophagy, can further accelerate
hepatocellular clearance and improve degradation of the mutant
protein in a mouse model of alpha1-antitrypsin [7]. This ﬁnding
has led to a phase 2 clinical trial using carbamazepine in patients
with severe alpha1-antitrypsin liver disease (ClinicalTrials.gov
NCT01379469).
In this month’s Journal, an article by Lin and colleagues
weaves these two threads from the Czaja and Perlmutter studies
together by exploring the treatment of fatty liver due to chronic
ethanol feeding or high fat diet by stimulating autophagy.
Building on their earlier study that demonstrated increased
autophagy in mice acutely fed ethanol [8], here Lin et al. report
that either carbamazepine or rapamycin (which also stimulates
autophagy, by suppressing mTOR activity) enhance macroauto-
phagy in cultured hepatocytes and reduce steatosis, injury and
ALT elevation in vivo following acute or chronic ethanol feeding.
In contrast, chloroquine, which blocks autophagy, exacerbates
steatosis and injury in these animals. Similarly, in mice fed a high
fat diet for 12 weeks, carbamazepine or rapamycin signiﬁcantly
reduces steatosis, hepatic and serum triglycerides and insulin
resistance. Because carbamazepine had no effect on several genes
regulating lipogenesis and fatty acid oxidation, the ﬁndings are
consistent with its beneﬁting fatty liver by increasing autophagy,
although more studies are needed to establish this effect on
autophagy as the primary mechanism of action, including more
extensive metabolic characterization of mice treated with the
drug.
The ﬁndings from this study are highly translational and rein-
force the potential utility of stimulating autophagic ﬂow to
improve fatty liver disease. Moreover, in animal models of NAFLD
there is a relative deﬁciency of autophagy, the mechanism of
which is not known [9]; in these models, genetic reconstitution
of autophagy attenuates features of the disease [9].
There are several gaps and a caveat that need to be addressed
before fully embracing autophagy stimulation as a therapy for
fatty liver disease, however. First, there is scant evidence that13 vol. 58 j 845–846
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autophagy is altered in human fatty liver diseases. Additionally,
the link between autophagy and insulin resistance needs further
clariﬁcation. Because insulin inhibits autophagy [10], the hyper-
insulinemia typical of NAFLD may be provoking autophagy deﬁ-
ciency rather than the other way around, although autophagy
may modify insulin sensitivity as well. Further studies are also
needed to deﬁnitely link the beneﬁcial effects of carbamazepine
to its induction of autophagy. Gene array studies combined
with pathway analysis might uncover additional downstream
responses to carbamazepine that could help suggest new thera-
peutic targets and drugs. From a commercial perspective, because
carbamazepine and rapamycin are both available as generic for-
mulations, it would be difﬁcult to attract a commercial sponsor
to support trials for fatty liver disease using these drugs alone.
However, because they are both established molecular entities,
the drugs might be used in combination with a novel experimen-
tal agent to enhance efﬁcacy in at least one arm of a potential
multi-arm clinical trial. Alternatively, since carbamazepine is pri-
marily used as an agent to treat neurologic diseases and has a
number of adverse effects, careful structure-activity studies
might uncover novel derivatives of the drug that preserve the
autophagy-inducing activity while eliminating the CNS effects.
This strategy would have the added beneﬁt of creating a new
molecular entity that could entice pharmaceutical companies to
support its development. A ﬁnal point is that while most studies
suggest that enhancing autophagy should reduce the risk of
neoplasia, at least a few indicate that the pathway also ampliﬁes
hepatitis virus replication and can enhance tumor cell metabo-
lism, so vigilance for these untoward effects would be warranted
if clinical trials are conducted, especially in patients with
cirrhosis, who are at higher risk for cancer.
An additional caveat concerns the collateral impact of manip-
ulating hepatic autophagy on non-hepatocytes. Speciﬁcally, we
have demonstrated that autophagy in hepatic stellate cells drives
hepatic ﬁbrogenesis in vivo since animals with stellate cell-spe-
ciﬁc defects in autophagic signaling have reduced ﬁbrosis follow-
ing toxic liver injury [11]; presumably, autophagy in this context
provides the fuel necessary to support the increased energy
demands of stellate cell activation. In fact, in our studies inhibi-
tion of autophagy with chloroquine enhances toxic liver injury
due to CCl4 in mice, however the animals have less ﬁbrosis
(unpublished results). Therefore, efforts to stimulate autophagy
in order to improve fatty liver disease must be mindful of the
potential for increasing ﬁbrosis, although if the ﬁbrogenic signals
from injured hepatocytes are sufﬁciently attenuated by autoph-
agy induction, this may not be a signiﬁcant concern. On the other846 Journal of Hepatology 201hand, cell-speciﬁc inhibition of autophagy in stellate cells might
be an attractive antiﬁbrotic strategy, provided that collateral
effects on other cell types (including endothelial cells, inﬂamma-
tory cells as well as hepatocytes) are minimized.
In summary, the emergence of autophagy as a pathway
central to hepatic homeostasis is highlighted by the ﬁndings of
Lin et al. in this issue of the Journal. ‘Going with the ﬂow’ of
autophagy merits serious consideration as a new strategy for
the treatment of fatty liver disease.Conﬂict of interest
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